Author

David Sarfati-Mizrahi

Universidad de Ciencias Médicas de Ciego de ÁvilaORCID 0009-0002-6558-6316Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Assay:proteomics· 2 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

Adolfo García‐SastreiD· 2 shared Alejandro Torres-FloresiD· 2 shared Bernardo Lozano-DubernardiD· 2 shared Constantino III Roberto López-MacíasiD· 2 shared Florian KrammeriD· 2 shared Georgina Paz-De la RosaiD· 2 shared Gustavo Peralta-SáncheziD· 2 shared Héctor Elías Chagoya-CortésiD· 2 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Adolfo García‐SastreORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Addressing SARS-CoV-2 Evolution: Neutralization of Emerging Variants of Concern by the AVX/COVID-12 'Patria' Vaccine Based on HexaPro-S Ancestral Wuhan Spike or Its Updated BA.2.75.2 Version

Gregorio Carballo‐Uicab, Gabriela Mellado‐Sánchez, Edith González‐González, Juana Salinas-Trujano, Ivette Mendoza-Salazar, Karina López-Olvera, Keyla Gómez-Castellano, Ma. Isabel Salazar, Jesús Miguel Torres-Flores, Héctor Elías Chagoya-Cortés, Georgina Paz-De la Rosa, Ignacio Mena, Oscar Rojas-Martínez, Jesús Horacio Lara Puente, Gustavo Peralta-Sánchez, , Juan Carlos Almagro

This study evaluates two SARS-CoV-2 vaccines, AVX/COVID-12 (V-Wu) and V-BA, showing V-BA provides better protection against Omicron subvariants while V-Wu offers broader coverage against multiple variants.

Frontiers in Immunology · May 19, 2025Peer-reviewedImmunology

Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate AVX/COVID-12 Activates T Cells and Is Recognized by Antibodies from COVID-19 Patients and Vaccinated

Alejandro Torres-Flores, Luis Alberto Ontiveros-Padilla, Ruth Lizzeth Madera-Sandoval, Araceli Tepale-Segura, Julián A. Gajón, Tania Rivera-Hernández, Eduardo Antonio Ferat-Osorio, Arturo Cérbulo‐Vázquez, Lourdes Arriaga‐Pizano, Laura C. Bonifaz, Georgina Paz-De la Rosa, Oscar Rojas-Martínez, Alejandro Suárez-Martínez, Gustavo Peralta-Sánchez, David Sarfati-Mizrahi, , Constantino III Roberto López-Macías

This paper evaluates the AVX/COVID-12 vaccine's ability to activate T cells and bind antibodies from vaccinated individuals and SARS-CoV-2-infected patients.

Frontiers in Immunology · May 30, 2024Peer-reviewedImmunology